Abstract library

431 results for "diagnostic-prognostic tissue biomarker".
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Conference:
Category: Basic
Presenting Author: Mr TAO CUI
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#2908 Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)
Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD student & CR Alexander Ney
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy
Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland
Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner
#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Chris Weston
Authors: Shah T, Sagar V, Neil D, Liu B, ...
#413 Expression of UCH-L1 in PETs and its Implications
Introduction: There is a lack of reliable biomarkers to distinguish benign from malignancy in pancreatic endocrine tumors (PETs) and to predict prognosis. Our previous study on insulinoma found the expression of UCH-L1 in these tumors. The diagnostic or prognostic value of this protein has not been well demonstrated in PETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Qiao X W, Tang L, Wan Y H, ...